drugset / Trial / NCT07523347

Efficacy and Safety of Oral Rivaroxaban in Cerebrosinovenous Thrombosis

NCT07523347

Completed 75 enrolled Muhammad Aamir Latif
RandomizedParallel-groupOpen-labelTreatment

Summary

The study seeks to fill the gaps regarding safety and efficacy of rivaroxaban and standard anticoagulant. therefore the current study was planned with the aim to determine the safety and efficacy of rivaroxaban and standard anticoagulant in the treatment of cerebrosinovenous thrombosis (CSVT).

Timeline

Start
2023-12-01
Primary completion
2025-12-31
Completion
2025-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject Rivaroxaban Other / unclassified Oral
Subject Warfarin Small molecule Oral